BUZZ-Tempus AI rises as it expands cancer research partnership with Gilead

Reuters04-09 20:49
BUZZ-<a href="https://laohu8.com/S/TEM">Tempus AI</a> rises as it expands cancer research partnership with <a href="https://laohu8.com/S/GILD">Gilead</a>

** Shares of healthcare AI firm Tempus AI TEM.O rise 1.5% to $47.99 premarket

** Co says it has expanded its multi-year partnership with Gilead GILD.O to support cancer drug research

** Collaboration gives Gilead wider access to Tempus’ real-world patient data and AI tools, which analyze medical records from cancer patients - TEM

** Gilead will use the platform to design clinical trials, choose drug targets and study treatment outcomes, co says

** Says partnership aims to speed up development of cancer medicines by combining Tempus’ data insights with Gilead’s drugmaking expertise

** Gilead has previously utilized TEM's data for its oncology research, including trial design, health outcomes analysis and clinical evidence

** As of last close, stock down ~20% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment